Journal
VACCINE
Volume 25, Issue 32, Pages 6028-6036Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.05.013
Keywords
h5N1 whole virus vaccine; vero cells
Categories
Funding
- NIAID NIH HHS [N01 AI005413, NO1-AI-05413/MBS-05413-24, N01-AI-05413] Funding Source: Medline
- PHS HHS [MBS-05413-24] Funding Source: Medline
Ask authors/readers for more resources
The rapid spread and the transmission to humans of avian influenza virus (H5N1) have induced world-wide fears of a new pandemic and raised concerns over the ability of standard influenza vaccine production methods to rapidly supply sufficient amounts of an effective vaccine. 14 We report here on a robust and flexible strategy which uses wild-type virus grown in a continuous cell culture (Vero) system to produce an inactivated whole virus vaccine. Candidate vaccines based on clade 1 and clade 2 influenza H5N1 strains were developed and demonstrated to be highly immunogenic in animal models. The vaccines induce cross-neutralising antibodies, highly cross-reactive T-cell responses and are protective in a mouse challenge model not only against the homologous virus but also against other H5N1 strains, including those from another clade. These data indicate that cell culture-grown whole virus vaccines, based on the wild-type virus, allow the rapid high yield production of a candidate pandemic vaccine. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available